Pacer Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $456M | Buy |
16,256,214
+62,886
| +0.4% | +$1.67M | 1.28% | 4 |
|
|
2025
Q4 | $403M | Sell |
16,193,328
-1,381,523
| -8% | -$34.8M | 1.03% | 19 |
|
|
2025
Q3 | $448M | Sell |
17,574,851
-2,284,449
| -12% | -$56.4M | 1.13% | 9 |
|
|
2025
Q2 | $481M | Sell |
19,859,300
-194,528
| -1% | -$4.54M | 1.2% | 6 |
|
|
2025
Q1 | $508M | Buy |
20,053,828
+17,957,928
| +857% | +$470M | 1.19% | 12 |
|
|
2024
Q4 | $55.6M | Buy |
2,095,900
+1,664,668
| +386% | +$45.2M | 0.12% | 188 |
|
|
2024
Q3 | $12.5M | Buy |
431,232
+20,769
| +5% | +$606K | 0.03% | 413 |
|
|
2024
Q2 | $11.5M | Sell |
410,463
-1,236,209
| -75% | -$34M | 0.03% | 407 |
|
|
2024
Q1 | $45.7M | Buy |
1,646,672
+39,023
| +2% | +$1.08M | 0.11% | 209 |
|
|
2023
Q4 | $46.3M | Sell |
1,607,649
-8,676,056
| -84% | -$262M | 0.13% | 177 |
|
|
2023
Q3 | $341M | Buy |
10,283,705
+2,411,773
| +31% | +$85.3M | 1.31% | 9 |
|
|
2023
Q2 | $289M | Buy |
7,871,932
+935,185
| +13% | +$36.4M | 1.16% | 8 |
|
|
2023
Q1 | $283M | Buy |
6,936,747
+2,597,274
| +60% | +$112M | 1.21% | 9 |
|
|
2022
Q4 | $222M | Buy |
4,339,473
+1,057,958
| +32% | +$50.7M | 1.14% | 7 |
|
|
2022
Q3 | $144M | Buy |
3,281,515
+714,906
| +28% | +$34.7M | 1% | 17 |
|
|
2022
Q2 | $135M | Buy |
2,566,609
+759,976
| +42% | +$38.7M | 1% | 14 |
|
|
2022
Q1 | $93.5M | Buy |
1,806,633
+1,066,899
| +144% | +$55.4M | 0.77% | 14 |
|
|
2021
Q4 | $43.7M | Sell |
739,734
-70,832
| -9% | -$3.51M | 0.45% | 27 |
|
|
2021
Q3 | $34.9M | Buy |
810,566
+387,780
| +92% | +$17.2M | 0.44% | 24 |
|
|
2021
Q2 | $16.6M | Buy |
422,786
+57,102
| +16% | +$2.22M | 0.24% | 59 |
|
|
2021
Q1 | $13.2M | Sell |
365,684
-24,132
| -6% | -$857K | 0.23% | 58 |
|
|
2020
Q4 | $14.3M | Sell |
389,816
-117,300
| -23% | -$4.3M | 0.27% | 55 |
|
|
2020
Q3 | $17.7M | Sell |
507,116
-79,981
| -14% | -$2.8M | 0.38% | 43 |
|
|
2020
Q2 | $18.2M | Buy |
587,097
+492,334
| +520% | +$16.7M | 0.37% | 50 |
|
|
2020
Q1 | $3.32M | Sell |
94,763
-572,764
| -86% | -$19.5M | 0.07% | 98 |
|
|
2019
Q4 | $24.8M | Buy |
667,527
+28,275
| +4% | +$1.01M | 1.12% | 13 |
|
|
2019
Q3 | $21.8M | Buy |
639,252
+77,566
| +14% | +$2.82M | 0.49% | 36 |
|
|
2019
Q2 | $23.1M | Buy |
561,686
+36,815
| +7% | +$1.46M | 0.56% | 25 |
|
|
2019
Q1 | $21.1M | Buy |
+524,871
| New | +$21M | 0.59% | 26 |
|
|
2018
Q4 | – | Sell |
-445,031
| Closed | -$18.6M | – | 912 |
|
|
2018
Q3 | $18.6M | Buy |
445,031
+28,674
| +7% | +$1.1M | 0.7% | 13 |
|
|
2018
Q2 | $14.3M | Buy |
416,357
+63,249
| +18% | +$2.16M | 0.65% | 14 |
|
|
2018
Q1 | $11.9M | Buy |
353,108
+70,330
| +25% | +$2.42M | 0.66% | 19 |
|
|
2017
Q4 | $9.72M | Buy |
282,778
+58,674
| +26% | +$2M | 0.68% | 16 |
|
|
2017
Q3 | $7.59M | Buy |
224,104
+20,359
| +10% | +$654K | 0.67% | 14 |
|
|
2017
Q2 | $6.49M | Buy |
203,745
+33,213
| +19% | +$1.05M | 0.64% | 15 |
|
|
2017
Q1 | $5.54M | Buy |
170,532
+14,021
| +9% | +$442K | 0.68% | 15 |
|
|
2016
Q4 | $4.82M | Buy |
156,511
+6,701
| +4% | +$205K | 0.69% | 19 |
|
|
2016
Q3 | $4.81M | Buy |
149,810
+11,194
| +8% | +$374K | 0.73% | 17 |
|
|
2016
Q2 | $4.63M | Buy |
138,616
+14,745
| +12% | +$471K | 0.73% | 17 |
|
|
2016
Q1 | $3.48M | Buy |
123,871
+16,264
| +15% | +$465K | 0.79% | 21 |
|
|
2015
Q4 | $3.3M | Buy |
+107,607
| New | +$3.39M | 0.77% | 23 |
|
|
2013
Q4 | $1.09M | Buy |
+36,785
| New | +$1.07M | 0.26% | 106 |
|
Other funds holding PFE
VCM
VPM
Pacer Advisors's PFE Position: Q1 2026 in Review
Pacer Advisors increased its Pfizer (PFE) stake by 0.39% in Q1 2026, buying an estimated $1.67M and bringing the position to 16,256,214 shares worth $456M. The position accounts for 1.28% of the portfolio, ranked #4.
Pacer Advisors first reported a position in PFE in Q4 2013 and has held it in 42 quarters since. The position peaked at $508M in Q1 2025. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Pacer Advisors held 16,256,214 shares of Pfizer worth $456M as of Q1 2026.
- Pacer Advisors bought 62,886 Pfizer shares in Q1 2026, an estimated $1.67M.
- Pfizer made up 1.28% of Pacer Advisors's portfolio in Q1 2026, its #4 holding.
- Pacer Advisors first reported a position in Pfizer in Q4 2013 and has held it in 42 quarters since.
- Pacer Advisors's Pfizer position peaked at $508M in Q1 2025.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.